Top 20 of Cervical Intraepithelial Neoplasia

Article title # Publications/# Citations

Natural history of cervicovaginal papillomavirus infection in young women.

1998: LBeardsley; RBierman; RDBurk; CJChang; GYHo;

265

Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions.

2007: Future II Study Group;

237

Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update.

2007: GMClifford; SFranceschi; BHoots; JKeys; LLindsay; JSSmith; RWiner;

236

The 2001 Bethesda System: terminology for reporting results of cervical cytology.

2002: Bethesda 2001 Workshop; Forum Group Members; DDavey; RKurman; AMoriarty; DO'Connor; MPrey; SRaab; ... MSherman; DSolomon; DWilbur; TWright; NYoung;

235

Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women.

2009: HPV PATRICIA Study Group; FYAoki; DApter; FXBosch; XCastellsagué; SNChow; DDescamps; GDubin; ... SGarland; KHardt; JHedrick; UJaisamrarn; DJenkins; HKitchener; MLehtinen; GLimson; PNaud; JPaavonen; WAPoppe; BRomanowski; JSalmerón; TFSchwarz; SRSkinner; FStruyf; ASzarewski; JCTeixeira; CMWheeler; TZahaf;

223

Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial.

2005: RPAndrade; KAAult; EBarr; DRBrown; RLCosta; MTEsser; AFerenczy; ARGiuliano; ... DMHarper; KUJansen; LAKoutsky; RJKurman; MLehtinen; LLupinacci; CMalm; SEOlsson; CAPetta; RRailkar; BMRonnett; AJSaah; HLSings; FESkjeldestad; MSteinwall; MHStoler; FJTaddeo; GMTamms; LLVilla; CMWheeler; JYu;

206

Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions.

2001 Jul-Aug: CAChen; GSChen; TMChen; ALCheng; YFHo; CYHsieh; CHHsu; MMHsu; ... SHJee; JYKo; MKLai; BRLin; JKLin; JTLin; WMing-Shiang; MHPan; YSPu; TSShen; CCTsai; YJWang; HSYu;

203

Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial.

2004 Nov 13-19: GlaxoSmithKline HPV Vaccine Study Group; MMBlatter; NSde Carvalho; GDubin; DGFerris; ELFranco; DMHarper; BInnis; ... DJenkins; APKorn; PNaud; WQuint; CMRoteli-Martins; ASchuind; JTeixeira; CWheeler; TZahaf;

199

Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial.

2006: HPV Vaccine Study group; SACosta Clemens; GDubin; ELFranco; DMHarper; DJenkins; ABMoscicki; BRomanowski; ... CMRoteli-Martins; ASchuind; CMWheeler;

197

A controlled trial of a human papillomavirus type 16 vaccine.

2002: Proof of Principle Study Investigators; FBAlvarez; KAAult; EBarr; DRBrown; LMChiacchierini; KUJansen; LAKoutsky; CMWheeler;

195

Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial.

2007: HPV PATRICIA Study Group; DLApter; FXBosch; XCastellsague; SNChow; NSde Carvalho; MDionne; GDubin; ... DMHarper; JAHedrick; UJaisamrarn; DJenkins; HCKitchener; MOLehtinen; GALimson; PNaud; JPaavonen; PPeeters; WQuint; JSalmerón; SRSkinner; BSpiessens; FStruyf; CMWheeler; SLWieting;

184

HPV screening for cervical cancer in rural India.

2009: AMBudukh; RChinoy; SDesai; KADinshaw; SHingmire; KJayant; SKane; RKelkar; ... VRKeskar; AKothari; SGMalvi; RMuwonge; BMNene; NPanse; RRajeshwarkar; RSankaranarayanan; SSShastri; RThorat;

134

Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer.

2007: Canadian Cervical Cancer Screening Trial Study Group; FCoutlée; EDuarte-Franco; AFerenczy; ELFranco; JHanley; MHMayrand; SRatnam; IRodrigues; SDWalter;

134

The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice.

2005: PECastle; AGGlass; MJKhan; ATLorincz; BBRush; MSchiffman; DRScott; MSherman; SWacholder;

123

Human papillomavirus and Papanicolaou tests to screen for cervical cancer.

2007: JDillner; KElfgren; OForslund; BGHansson; BJohansson; PNaucler; TRådberg; WRyd; ... ERylander; AStrand; BStrander; STörnberg; GWadell;

114

High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up.

2006: AAndersson-Ellstrom; RPAndrade; EBarr; JBryan; RLCosta; KElfgren; MTEsser; KGiacoletti; ... JHøye; OEIversen; GvKrogh; MLehtinen; LLupinacci; CMalm; SEOlsson; JPaavonen; CAPetta; RRailkar; GRiis-Johannessen; AJSaah; HLSings; MSteinwall; FJTaddeo; GMTamms; LLVilla;

112

Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial.

2010: New Technologies for Cervical Cancer screening (NTCC) Working Group; FCarozzi; MConfortini; JCuzick; PDalla Palma; LDe Marco; ADel Mistro; BGhiringhello; ... AGillio-Tos; PGiorgi-Rossi; SGirlando; CNaldoni; PPierotti; RRizzolo; GRonco; PSchincaglia; NSegnan; MZappa; MZorzi;

109

American Cancer Society guideline for the early detection of cervical neoplasia and cancer.

2002 Nov-Dec: American Cancer Society; CCohen; HJEyre; ABMoscicki; CDRunowicz; DSaslow; RASmith; DSolomon;

108

An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis.

2004: EGiraudo; DHanahan; MInoue;

107

Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort study.

2001: ABailey; SCollins; JEllis; PPrior; TPRollason; HWinter; CBWoodman; MYates; LSYoung;

102